Insider Trading Alert - ARP, AKRX And IPXL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 19, 2014, 147 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $80.88 to $19,640,406.96.

Highlighted Stocks Traded by Insiders:

Atlas Resource Partners (ARP) - FREE Research Report

Cohen Jonathan Z, who is Vice Chairman at Atlas Resource Partners, bought 20,000 shares at $19.74 on May 19, 2014. Following this transaction, the Vice Chairman owned 244,638 shares meaning that the stake was reduced by 8.9% with the 20,000-share transaction.

Cohen Edward E, who is Chairman & CEO at Atlas Resource Partners, bought 40,000 shares at $19.83 on May 19, 2014. Following this transaction, the Chairman & CEO owned 435,141 shares meaning that the stake was reduced by 10.12% with the 40,000-share transaction.

The shares most recently traded at $20.03, up $0.20, or 0.98% since the insider transaction. Historical insider transactions for Atlas Resource Partners go as follows:

  • 4-Week # shares bought: 24,475
  • 12-Week # shares bought: 24,475
  • 24-Week # shares bought: 24,475
  • 24-Week # shares sold: 8,250

The average volume for Atlas Resource Partners has been 919,600 shares per day over the past 30 days. Atlas Resource Partners has a market cap of $1.3 billion and is part of the basic materials sector and energy industry. Shares are down 2.78% year-to-date as of the close of trading on Monday.

Atlas Resource Partners, L.P. operates as an independent developer and producer of natural gas, crude oil, and natural gas liquids in the United States. The company operates in three segments: Gas and Oil Production, Well Construction and Completion, and Other Partnership Management. The stock currently has a dividend yield of 11.96%. Currently, there is 1 analyst who rates Atlas Resource Partners a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARP - FREE

TheStreet Quant Ratings rates Atlas Resource Partners as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Atlas Resource Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Akorn (AKRX) - FREE Research Report

Bonaccorsi Joseph, who is Secretary at Akorn, bought 5,000 shares at $26.83 on May 19, 2014. Following this transaction, the Secretary owned 78,314 shares meaning that the stake was reduced by 6.82% with the 5,000-share transaction.

Rai Rajat, who is Chief Executive Officer at Akorn, bought 5,000 shares at $26.76 on May 19, 2014. Following this transaction, the Chief Executive Officer owned 31,271 shares meaning that the stake was reduced by 19.03% with the 5,000-share transaction.

The shares most recently traded at $27.31, up $0.55, or 2.01% since the insider transaction. Historical insider transactions for Akorn go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares sold: 20,000

The average volume for Akorn has been 996,800 shares per day over the past 30 days. Akorn has a market cap of $2.8 billion and is part of the health care sector and drugs industry. Shares are up 10.99% year-to-date as of the close of trading on Monday.

Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. The company has a P/E ratio of 60.9. Currently, there are 6 analysts who rate Akorn a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AKRX - FREE

TheStreet Quant Ratings rates Akorn as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Akorn Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Impax Laboratories (IPXL) - FREE Research Report

Terreri Peter R, who is Director at Impax Laboratories, sold 950 shares at $26.03 on May 19, 2014. Following this transaction, the Director owned 45,186 shares meaning that the stake was reduced by 2.06% with the 950-share transaction.

Fleming Nigel, who is Director at Impax Laboratories, sold 1,900 shares at $25.72 on May 19, 2014. Following this transaction, the Director owned 11,266 shares meaning that the stake was reduced by 14.43% with the 1,900-share transaction.

The shares most recently traded at $26.41, up $0.69, or 2.61% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 225,385
  • 12-Week # shares sold: 229,385
  • 24-Week # shares sold: 232,385

The average volume for Impax Laboratories has been 796,200 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.8 billion and is part of the health care sector and drugs industry. Shares are up 4.34% year-to-date as of the close of trading on Monday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 2617.0. Currently, there are 2 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook's Investors Have a Big Day Ahead

Facebook's Investors Have a Big Day Ahead

The Global Stock Market Rout Spreads Across the World

The Global Stock Market Rout Spreads Across the World